Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Heterocyclic compound >  Pyridine compound >  5-Bromo-3-methoxy-2-methylpyridine

5-Bromo-3-methoxy-2-methylpyridine

Basic information Safety Supplier Related

5-Bromo-3-methoxy-2-methylpyridine Basic information

Product Name:
5-Bromo-3-methoxy-2-methylpyridine
Synonyms:
  • 5-Bromo-3-methoxy-2-methylpyridine
  • Pyridine, 5-bromo-3-methoxy-2-methyl-
CAS:
1150617-80-3
MF:
C7H8BrNO
MW:
202.05
Mol File:
1150617-80-3.mol
More
Less

5-Bromo-3-methoxy-2-methylpyridine Chemical Properties

Boiling point:
219℃
Density 
1.452
Flash point:
86℃
storage temp. 
Inert atmosphere,Room Temperature
pka
3.67±0.10(Predicted)
form 
solid
color 
Beige
More
Less

Safety Information

HS Code 
2933399990
More
Less

5-Bromo-3-methoxy-2-methylpyridine Usage And Synthesis

Synthesis

1142191-57-8

75-16-1

1150617-80-3

In Step 6-iv of Scheme 6, 2,5-dibromo-3-methoxypyridine (Compound 1020, 5 g, 18.73 mmol) was dissolved in anhydrous tetrahydrofuran (THF, 94 mL), followed by the addition of tetrakis(triphenylphosphine)palladium (Pd(PPh3)4, 2.16 g, 1.873 mmol). The reaction mixture was cooled in an ice bath and a 3:1 THF/toluene solution of methylmagnesium bromide (17.4 mL, 1.4 M, 24.35 mmol) was added slowly and dropwise. After removing the ice bath, the reaction mixture was heated to reflux. After stirring under reflux conditions for 1 hour, 3 mL of methylmagnesium bromide solution was added additionally. After continuing to stir at reflux for 20 minutes, 2 mL of methylmagnesium bromide solution was added again. The reaction mixture was continued to be stirred under reflux for 1 hour and subsequently cooled to room temperature. The organic layer was separated by adding ether and 1N hydrochloric acid (HCl) for quenching and washed with 1N HCl. The aqueous phase was extracted three times with ether. The aqueous phase was adjusted to alkaline with 2N sodium hydroxide (NaOH) and extracted three times with ethyl acetate. The ethyl acetate extracts were combined, dried with anhydrous sodium sulfate (Na2SO4) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 0-25% ethyl acetate/hexane) to afford 5-bromo-3-methoxy-2-methylpyridine (Compound 1021, 2.7 g, 71% yield): ESMS (M + H) 202, 204.5-Bromo-2-ethyl-3-methoxypyridine was prepared using a similar method: ESMS (M + H) 216, 218. 1H NMR (CDCl3) δ 8.2 (d, 1H), 7.2 (d, 1H), 3.8 (s, 3H), 2.8 (q, 2H), 1.2 (t, 3H).

References

[1] Patent: WO2010/96389, 2010, A1. Location in patent: Page/Page column 46; 48
[2] Patent: WO2010/135014, 2010, A1. Location in patent: Page/Page column 53-55

5-Bromo-3-methoxy-2-methylpyridineSupplier

Adamas Reagent, Ltd.
Tel
400-6009262 15618770481
Email
yhx@titansci.com
Chiba Pharmaceutical Science and technology Co, Ltd.
Tel
0531-81313138 13066006660
Email
chibapharm@foxmail.com
Jiangsu Aikon Biopharmaceutical R&D co.,Ltd.
Tel
025-66113011 17714375163
Email
cfzhang@aikonchem.com
Shanghai Jian Chao Chemical Technology Co., Ltd.
Tel
150-2103-5486 18017383231
Email
983544897@qq.com
Yancheng KangdiSen Pharmaceutical Co., Ltd.
Tel
13812573443
Email
tongbenwan22@163.com